Akshay Vaishnaw, EVP, R&D, CMO at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 8,750 shares at $115.29 ($1.0M) on 2015-03-17, disclosed to the SEC on 2015-03-19.
Scheduled sale ($1.0M) by EVP, R&D, CMO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $115.29 | 1,224 | $141K | 13.8% |
| 2 | $116.34 | 3,802 | $442K | 43.3% |
| 3 | $117.35 | 2,080 | $244K | 23.9% |
| 4 | $118.16 | 1,000 | $118K | 11.6% |
| 5 | $119.38 | 644 | $77K | 7.5% |
| Total | $116.86 avg | 8,750 |
| $1.0M |
| 100% |
| Filing → |
| SRRK | SELL | 2025-05-30 | $353K | — | Filing → |
| ALNY | SELL | 2023-08-07 | $1.4M | — | Filing → |
| ALNY | SELL | 2023-04-28 | $839K | — | Filing → |